On June 13, 2013, the U.S. Supreme Court issued its decision in Association for Molecular Pathology v. Myriad Genetics, Inc., a case involving the eligibility of Myriad’s patent claims to isolated DNA BRCA1 polypeptides.

The Court held that natural isolated DNA is not patent-eligible, while synthetically made complementary DNA (cDNA) is patent-eligible.

Click here to view decision.